Cell Freezing Media Global Market Report 2025

The cell freezing media market size has grown rapidly in recent years. It will grow from $1.59 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to rising demand for biopharmaceuticals, increasing focus on cell based therapies, a surge in stem cell banking activities, expansion of clinical research involving primary cells, and rising government funding for regenerative medicine.

The cell freezing media market size is expected to see rapid growth in the next few years. It will grow to $2.7 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to rising investments in cell and gene therapy development, increasing emphasis on personalized medicine applications, growing need for high quality cell storage solutions, surge in biobanking initiatives across emerging regions, and rising prevalence of chronic and genetic disorders. Major trends in the forecast period include technological advancements in serum free and chemically defined freezing media, progress in cryoprotectant formulations to reduce cell toxicity, innovations in automation and closed system freezing processes, developments in controlled rate and programmable freezing equipment, and advancements in the integration of artificial intelligence for process optimization.

The rising demand for personalized medicine is expected to propel the growth of the cell freezing media market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Cell freezing media supports personalized medicine by providing reliable cryopreservation solutions that preserve patient specific cells, tissues, and biologics. It ensures high post thaw viability and functionality, supporting the development of tailored therapies and improving treatment outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition PMC, a US based nonprofit organization, the United States Food and Drug Administration approved twenty six new personalized medicines in 2023, a significant increase from the twelve approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the cell freezing media market.

Major companies operating in the cell freezing media market are focusing on developing advanced products such as specialized cryopreservation media to boost efficiency, enhance cell viability, and accelerate therapeutic development. Specialized cryopreservation media refer to formulated solutions designed to preserve cells, tissues, or biological materials at very low temperatures while maintaining their viability, functionality, and structural integrity. For instance, in April 2024, Pluristyx Inc., a US based biotechnology company, launched PluriFreeze. It is a xeno free and serum free cGMP manufactured media designed to improve post thaw recovery and function of a wide range of cell types including stem cells and immune cells. It is engineered to provide a robust, ready to use formulation that ensures high cell viability and functionality, supporting the transition of therapies from research to clinical application. PluriFreeze improves post thaw cell viability, manufacturing efficiency, and reproducibility in stem cell and cell therapy development processes.

In April 2025, BioLife Solutions Inc., a US based biotechnology company, acquired PanTHERA CryoSolutions Inc. for an undisclosed amount. With this acquisition, BioLife Solutions gains access to PanTHERA’s proprietary ice recrystallization inhibitor IRI technology, thereby enhancing its cryopreservation media portfolio while improving product performance, research reach, and customer value in cell and gene therapy biomanufacturing. PanTHERA CryoSolutions Inc. is a Canada based biotechnology company specializing in the development and manufacture of cell freezing media and cryopreservation solutions.

Major companies operating in the cell freezing media market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, FUJIFILM Corporation, Lonza Group Ltd., Avantor Inc., Sartorius AG., BioRad Laboratories Inc., Diploma plc, BioTechne Corporation, Miltenyi Biotec GmbH, Stemcell Technologies Inc., Vitrolife AB, American Type Culture Collection (ATCC), Bio-Life Solutions Inc., Nacalai Tesque Inc., PromoCell GmbH, Nippon Genetics Co. Ltd., Nippon Zenyaku Kogyo Co. Ltd., Quality Biological Inc.

North America was the largest region in the cell freezing media market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cell freezing media report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell freezing media market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The cell freezing media market research report is one of a series of new reports that provides cell freezing media market statistics, including the cell freezing media industry global market size, regional shares, competitors with the cell freezing media market share, detailed cell freezing media market segments, market trends, and opportunities, and any further data you may need to thrive in the cell freezing media industry. This cell freezing media market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cell freezing media is a specialized solution used to preserve living cells at very low temperatures, usually in liquid nitrogen, to maintain their viability and functionality for long periods. It typically contains cryoprotective agents that stop ice crystal formation and protect cell integrity during the freezing and thawing process. This media enables long term storage of biological samples for research, therapeutic, or diagnostic purposes, ensuring that cells remain healthy and usable after thawing.

The main types of cell freezing media include dimethyl sulfoxide (DMSO), glycerol, sucrose, ficoll, and serum based media. Dimethyl sulfoxide (DMSO) is an organic solvent commonly used as a cryoprotectant in cell freezing media to prevent ice crystal formation and support cell viability during cryogenic storage. The different cell culture types involved are suspension cell culture, 2D cell culture, 3D cell culture, and others and are distributed through various channels including direct sales, distributors, ecommerce platforms, retail outlets, and specialized scientific instrumentation suppliers. It is used in stem cell research, embryonic cell preservation, hematopoietic cell preservation, tissue sample storage, and gene therapy applications, and serves several end users such as academic research institutions, biotechnology companies, pharmaceutical companies, clinical laboratories, and contract research organizations (CROs).

The cell freezing media market consists of sales of cryovials, freezing containers, cryogenic storage bags, controlled-rate freezers, cryopreservation buffers, and freezing solution kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.